Researchers assessed the efficacy and safety of repository corticotropin injection in patients with relapsing-remitting multiple sclerosis relapse with an inadequate response to high-dose corticosteroids.
Using an in vitro model of decreased heterogeneous nuclear ribonucleoprotein A1 (A1), researchers sought to determine the impact of A1 nuclear function loss on neuronal health and viability.
Presenting at CMSC 2021, researchers analyzed the long-term safety of satralizumab, a humanized monoclonal antibody, in patients with neuromyelitis optica spectrum disorder from the SAkura trials.
Researchers assessed the ability of an online continuing medical education activity for neurologists to improve the knowledge of potential adverse effects associated with disease-modifying therapies for multiple sclerosis.
In this interim analysis, researchers reported the 1-year efficacy and safety data of ocrelizumab in treatment-naïve patients with early-stage relapsing-remitting multiple sclerosis.
Presented at CMSC 2021, researchers sought to develop a tele-monitoring tool that allows patients with multiple sclerosis to follow-up on their disease with help from their care team.
Presenting at CMSC 2021, researchers examined the relationship between cognition, patient-reported outcomes of Patient Determined Disease Steps and Ability to Participate in Social Roles and Activities-Short Form.
Presenting at the CSMC 2021, researchers highlighted the international consensus 2021 revisions to the guidelines on MRI in multiple sclerosis (MS), merging recommendations from 3 MS groups.
In a post-hoc analysis presented at CMSC 2021, researchers evaluated the effect of evobrutinib, a Bruton’s tyroskine kinase inhibitor, on blood neurofilament light chain level, a biomarker of neuroaxonal damage in multiple sclerosis.
Researchers sought to compare the frequency, racial differences, neurologic phenotype, and outcome of attacks that required ventilator support in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
